Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Deals
  5. Alliances Collaborations Licensing
  6. Licensing

Licensing

March 16, 2023

Daiichi torches Esperion’s Nexletol milestone promises

Despite assurances by Esperion, Daiichi is refusing to pay up after the Clear Outcomes disappointment.

Thumbnail
February 27, 2023

Destiny swallows dilution to push microbiome project forward

Article image
Vantage logo
February 23, 2023

Astra buys itself a second shot at the Claudin18.2 goal

Article image
Vantage logo
February 07, 2023

Bristol exit clips Dragonfly’s wings

Article image
Vantage logo
January 23, 2023

The world's twelfth VEGF drug will be sold by Takeda

The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.

Article image
Vantage logo
January 20, 2023

Asco-GI 2023 – Keytruda looms over zanidatamab's second shot

Article image
Vantage logo
January 11, 2023

Biopharma’s bolt-on bonanza is set to continue

With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?

Article image
Vantage logo
January 09, 2023

JP Morgan 2023 – licensing deal flurry offers limited cash up front

Article image
Vantage logo
December 30, 2022

Clinical and corporate developments over the Christmas period

A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.

Article image
Vantage logo
December 08, 2022

Vertex taps Entrada for another try at myotonic dystrophy

Article image
Vantage logo
December 07, 2022

Spending Duggan's dollars, courtesy of Summit

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up